Trial Profile

A Phase 0 Study Using the CIVO Platform to Evaluate Intratumoral Microdoses of Motolimod Singly and in Combination With Nivolumab in Patients With Head and Neck Cancer

Status: Discontinued

Phase of Trial: Phase 0

Latest Information Update: 15 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Motolimod (Primary) ; Nivolumab (Primary)
Indications Cancer metastases; Head and neck cancer; Squamous cell cancer
Focus Biomarker; Pharmacodynamics
Sponsors Presage Biosciences

Most Recent Events

06 Apr 2022 Status changed from recruiting to discontinued due to partner termination.
12 May 2021 Planned End Date changed from 31 Aug 2021 to 31 Mar 2022.
12 May 2021 Planned primary completion date changed from 31 Aug 2021 to 31 Dec 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com